Literature DB >> 12473270

Seronegative spondyloarthritides.

Ignazio Olivieri1, Astrid van Tubergen, Carlo Salvarani, Sjef van der Linden.   

Abstract

Epidemiological studies on the spondyloarthritides have been hindered in the past by the lack of adequate classification criteria for the whole group of these diseases. Using the Amor and the European Spondyloathropathy Study Group (ESSG) criteria the total prevalence of such diseases has been found to be higher than estimated in the past. The prevalence of ankylosing spondylitis varies across populations, but closely parallels the frequency of HLA B27-associated subtypes. The lack of well established criteria for reactive arthritis and the varying expression of its clinical manifestations are the principal reasons for the under-reporting of the true prevalence and incidence of this type of spondyloarthritis. Few data exist on the prevalence and incidence of psoriatic arthritis. A recent European study on an inception cohort of patients having inflammatory bowel disease has evaluated the prevalence of spondyloarthritis using the ESSG criteria. Of the patients studied, 18% met these criteria. Undifferentiated spondyloarthritis is one of the most frequent spondyloarthritides. It also includes a number of different subtypes.

Entities:  

Mesh:

Year:  2002        PMID: 12473270     DOI: 10.1053/berh.2002.0263

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  15 in total

1.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

2.  Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.

Authors:  J Askling; L Klareskog; P Blomqvist; M Fored; N Feltelius
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

Review 3.  Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Carlo Palazzi; Angela Padula; Reuven Mader; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

4.  Which is the dominant factor for perception of rheumatic pain: meteorology or psychology?

Authors:  Hasan Fatih Cay; Ilhan Sezer; Mehmet Z Firat; Cahit Kaçar
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

5.  Treating reactive arthritis: insights for the clinician.

Authors:  John D Carter
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

6.  Psoriatic arthritis: pharmacoeconomic considerations.

Authors:  Ignazio Olivieri; Lorenzo Giovanni Mantovani; Salvatore D'Angelo; Angela Padula; Simona de Portu
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

7.  Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis.

Authors:  John D Carter; Hervé C Gérard; Luis R Espinoza; Louis R Ricca; Joanne Valeriano; Jessica Snelgrove; Cynthia Oszust; Frank B Vasey; Alan P Hudson
Journal:  Arthritis Rheum       Date:  2009-05

8.  Biopsychosocial determinants of physical and mental fatigue in patients with spondyloarthropathy.

Authors:  Deborah Da Costa; Michel Zummer; Mary-Ann Fitzcharles
Journal:  Rheumatol Int       Date:  2009-12-20       Impact factor: 2.631

Review 9.  Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Authors:  Roy Fleischmann; Imran Iqbal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf related protein-1 in ankylosing spondylitis.

Authors:  Jun-Hui Xiong; Jian Liu; Jian Chen
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.